BCAL Diagnostics Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

11.87

EPS

—

Div Yield, %

—

Shrs. gr., 5y

2.74%

Rev. gr., 5y

64.37%

Revenues

+8.60%

Net income

-6m

L+26.44%

CFO

-5m

L-25.21%

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

BCAL Diagnostics Limited, a biotechnology company, engages in developing a non-invasive laboratory blood test for the detection of breast cancer. It develops BCAL test, a lipid biomarker blood test with the potential to be used for breast cancer prevention, screening, and monitoring; and in vitro diagnostic test (IVD) that confirms a fingerprint of lipid biomarkers extracted from extracellular vesicles from a patient's plasma or blood sample to diagnose the presence of breast cancer cells in a patient's body. The company was incorporated in 2010 and is headquartered in Sydney, Australia.

URL

https://www.bcaldiagnostics.com/

IPO date

Jul 21, 2021

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title AUD in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY
Title AUD in thousands, except ratios and share amounts	2024‑06	2023‑06	2022‑06	2021‑06	2020‑06	2019‑06	2018‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT